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of liver pathology by MRTo the Editor:
We welcome the response from Guiu et al. regarding
our recently published study [1]. We fully agree that for
MR methods to become a clinical tool, standardization
of the techniques is required. Our results were obtained
at 1.5 T, which remains the predominant clinical MRI
system. The authors fully recognise that there will be
beneﬁts in using 3 T, but the aim of this paper was to
present results that are relevant to the broader clinical
community.
The lack of a true “gold standard” is a potential lim-
iting factor for assessing the potential of new methods.
The latter point has been recently discussed in an edito-
rial and several articles in this Journal (vol. 50, 2009)
earlier this year. In the absence of a true “gold standard”
our analysis is based on clinically accepted measures,
scored by a single expert in liver histopathology (co-
author A.C.). MRS is not a clinically accepted measure.
We intentionally used the combined peak intensity
from CH2 + CH3 in the spectra, as we argue that the
CH3 signal contributes to the lipid fraction in both
imaging methods. The Dixon method uses TE values
that result in the water and CH2 protons being p radians
out-of-phase, based on the frequency shift between the
protons. The small frequency diﬀerence between CH2and CH3 protons, results in the CH3 spins being almost
out-of-phase and so also contributes to the net lipid sig-
nal. Given the separation of the CH2 and CH3 is only
0.4 ppm, (25.5 Hz at 1.5 T), the fat saturation methods
cannot suppress only CH2 protons, but also signiﬁcantly
suppress the CH3 signal.
Cirrhosis can be associated with increased liver iron
[2]. We suggest caution in assuming that liver ﬁbrosis
universally increases T2, particularly as increased iron
decreases T2.
The conclusions presented are consistent with the dif-
ference in scoring lipid content by the two methods. MR
methods measure lipid fraction per unit volume, irre-
spective of the hepatocyte count in the volume. The his-
tology method scores lipid content as hepatocytes with
visible fat. The number of hepatocyte nuclei per unit
volume decreased with ﬁbrosis, consistent with reduced
hepatocytes per unit volume with ﬁbrosis.
In conclusion, a combined approach should be the
goal for non-invasive measurement of liver pathology
by MR. Lipid content or ﬁbrosis are unlikely to be
universally measured in isolation, particularly without
a measure of iron content. However, with a combination
of lipid selective imaging, relaxometry, diﬀusion, spec-
troscopy and elastography, the future looks promising.
d1084 Letters to the Editor / Journal of Hepatology 51 (2009) 1082–1090References
[1] McPherson S, Jonsson JR, Cowin GJ, O’Rourke P, Clouston AD,
Volp A, et al. Magnetic resonance imaging and spectroscopy
accurately estimate the severity of steatosis provided the stage of
ﬁbrosis is considered. J Hepatol 2009;51:389–397.
[2] Stuart KA, Fletcher LM, Clouston AD, Lynch SV, Purdie DM,
Kerlin P, et al. Increased hepatic iron and cirrhosis: no evidence for
an adverse eﬀect on patient outcome following liver transplanta-
tion. Hepatology 2000;32:1200–1207.
Gary J. Cowin
Centre for Magnetic Resonance, The University of
Queensland, German Sciences Building, St. Lucia,
Brisbane 4072, Australia
Tel.: +61 07 33658378; fax: +61 07 33653833.
E-mail address: gary.cowin@cmr.uq.edu.au
(G.J. Cowin)
Julie R. Jonsson
School of Medicine, Southern Clinical Division,
The University of Queensland, Brisbane, Australia
Stuart McPherson
School of Medicine, Southern Clinical Division,
The University of Queensland, Brisbane, AustraliaUrsodeoxycholic acid and p
EASL and AASL
To the Editor:
We read with interest the recent EASL Clinical Prac-
tice Guidelines on management of cholestatic liver dis-
ease [1]. We would like to congratulate the authors on
the correct grading of evidence for the use of ursodeoxy-
cholic acid (UDCA) in patients with primary biliary cir-
rhosis (PBC) but at the same time we would like to
challenge them about the interpretation of data.
Levels of evidence are designed as objective tools
based on widely accepted deﬁned criteria. The authors
correctly used a grade II-2/B1 recommendation for use
of UDCA in PBC, as data to support this are only avail-
able from “cohort or case–control analytical studies”. In
contrast, the recent AASLD clinical practice guidelines
[2] give a diﬀerent level of evidence for use of UDCA,
which is Class I, level A i.e. data to support this are
“derived from multiple randomized clinical trials or
meta-analyses”. This grading is methodologically incor-
rect and probably reﬂects opinion rather than evidence.
In fact, no single randomized controlled trial to date has
demonstrated a signiﬁcant eﬀect of UDCA in terms of
survival or liver transplantation, and neither have a
meta-analysis nor a Cochrane review, which evaluated
all randomized trials [3,4].
Although the authors of the EASL guidelines criticize
the published meta-analyses [3,4] for including studies
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D guidelines
ith short duration or with use of inadequate doses of
DCA, this criticism is not justiﬁed. The Cochrane re-
iew with updated and longer follow-up data still failed
o ﬁnd beneﬁt of UDCA [3], and sensitivity analyses
egarding UDCA dose in both meta-analyses showed
o diﬀerence between standard doses (>13 mg/kg) ver-
us lower doses with respect to major outcome measures
3,4]. Even a selective analysis of raw data from the
rench, Canadian and Mayo cohorts showed a possible
eneﬁt of UDCA only in patients with moderate and se-
ere disease [5], in whom currently even those clinicians
ho feel UDCA is eﬀective, acknowledge that it is less
ikely to exert a beneﬁcial therapeutic eﬀect.
As regards the interpretation of evidence, the crucial is-
ue is the fact that in those studies in which cross-over
rom placebo or no treatment to UDCA occurred, (after
pproximately 2 years) the cross-over patients deterio-
ated despite using UDCA [4]. A potential solution to
valuate this paradox was given in correspondence from
s [6]. Nevertheless, our suggestions for analysis have
ever been taken up. However, we acknowledge that in
arly stage and/or asymptomatic PBC, UDCAmay have
eneﬁt – but conclusive evidence is lacking. Data to sup-
ort the use of UDCA in early asymptomatic PBC needs
trengthening. Indeed, the “Paris” and “Barcelona” crite-
ia mentioned by the authors, refer to cohorts with no
